Simufilam Reverses Aberrant Receptor Interactions of Filamin A in Alzheimer’s Disease

Simufilam is a novel oral drug candidate in Phase 3 clinical trials for Alzheimer’s disease (AD) dementia. This small molecule binds an altered form of filamin A (FLNA) that occurs in AD. This drug action disrupts FLNA’s aberrant linkage to the α7 nicotinic acetylcholine receptor (α7nAChR), thereby...

Full description

Bibliographic Details
Main Authors: Hoau-Yan Wang, Erika Cecon, Julie Dam, Zhe Pei, Ralf Jockers, Lindsay H. Burns
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/24/18/13927

Similar Items